- Home
- HLVX vs AGEN Comparison
HLVX vs AGEN Comparison
Compare HLVX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- AGEN
- Stock Information
- Founded
- HLVX 2020
- AGEN 1994
- Country
- HLVX United States
- AGEN United States
- Employees
- HLVX N/A
- AGEN N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HLVX Health Care
- AGEN Health Care
- Exchange
- HLVX Nasdaq
- AGEN Nasdaq
- Market Cap
- HLVX 105.2M
- AGEN 87.7M
- IPO Year
- HLVX 2022
- AGEN 2000
- Fundamental
- Price
- HLVX $2.15
- AGEN $5.96
- Analyst Decision
- HLVX Hold
- AGEN Strong Buy
- Analyst Count
- HLVX 1
- AGEN 3
- Target Price
- HLVX $2.00
- AGEN $16.33
- AVG Volume (30 Days)
- HLVX 364.7K
- AGEN 1.5M
- Earning Date
- HLVX 08-07-2025
- AGEN 08-07-2025
- Dividend Yield
- HLVX N/A
- AGEN N/A
- EPS Growth
- HLVX N/A
- AGEN N/A
- EPS
- HLVX N/A
- AGEN N/A
- Revenue
- HLVX N/A
- AGEN $99,524,000.00
- Revenue This Year
- HLVX N/A
- AGEN $25.31
- Revenue Next Year
- HLVX N/A
- AGEN N/A
- P/E Ratio
- HLVX N/A
- AGEN N/A
- Revenue Growth
- HLVX N/A
- AGEN N/A
- 52 Week Low
- HLVX $1.34
- AGEN $1.38
- 52 Week High
- HLVX $2.17
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- HLVX 61.80
- AGEN 54.03
- Support Level
- HLVX $2.07
- AGEN $5.67
- Resistance Level
- HLVX $2.16
- AGEN $6.96
- Average True Range (ATR)
- HLVX 0.07
- AGEN 0.61
- MACD
- HLVX -0.00
- AGEN -0.07
- Stochastic Oscillator
- HLVX 89.47
- AGEN 46.09
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).